Milk Thistle (Silybum marianum — Silymarin)

May reverse liver scarring in fatty liver

Silymarin is a mixture of flavonolignans from the seed: silybin A and B (together ~50–70%), isosilybin, silychristin, silydianin, and the flavonoid taxifolin. In cell and animal models it inhibits activation of hepatic stellate cells (the cells that turn into collagen-producing myofibroblasts and scar the liver), dampens NF-κB signalling, and supports glutathione. (Animal–in-vitro)

The best human test is a 48-week, double-blind RCT in Malaysia of 99 adults with biopsy-proven NASH, using 700 mg silymarin three times daily:¹

• Primary endpoint missed: a ≥30% drop in NAFLD activity score occurred in 32.7% on silymarin vs 26.0% on placebo (not significant).
• Fibrosis improved: 22.4% vs 6.0% had a ≥1-stage improvement in fibrosis on repeat biopsy, and 24.2% vs 2.3% had a ≥30% fall in liver stiffness. Non-invasive fibrosis scores (APRI, FIB-4, NAFLD fibrosis score) also fell on silymarin only.

So silymarin didn't clear fat or inflammation, but it may have reversed some scarring — the part of fatty liver disease that actually predicts outcomes. Because fibrosis was a secondary endpoint, the authors themselves call it unconfirmed. (Moderate — one well-run biopsy trial; secondary endpoint) The fatty liver itself is still a metabolic problem, handled by diet (see Linoleic Acid and Metabolic Health); silymarin is an adjunct.

Lowers blood sugar

In a 4-month double-blind trial in 51 Iranian patients with type 2 diabetes, 200 mg silymarin three times daily on top of standard therapy lowered HbA1c, fasting glucose, total and LDL cholesterol, triglycerides and liver enzymes compared with placebo.² Several later small trials, mostly from Iran and India, point the same way. Proposed mechanisms include lower hepatic glucose output and less oxidative stress in β-cells. (Moderate — consistent direction, but small trials from a narrow set of centers)

Protects the liver from toxins and alcohol

Mushroom poisoning

Silibinin blocks the liver-cell uptake transporter (OATP1B3) that lets α-amanitin, the Amanita death-cap toxin, into hepatocytes. IV silibinin (Legalon SIL) is used for death-cap poisoning in Europe, and it's the clearest pharmacological action milk thistle has. But that's an IV drug at hospital doses, not a capsule. (Moderate — case series and clinical use, no RCTs; ethical constraints)

Alcoholic cirrhosis

The two classic RCTs disagree. Ferenci et al. (1989, 170 patients, 140 mg three times daily) reported better 4-year survival on silymarin, driven by the alcoholic-cirrhosis subgroup.³ Parés et al. (1998, 200 alcoholic cirrhotics, 150 mg three times daily for 2 years) found no effect on survival or disease course.⁴ Continued drinking in both cohorts muddies either result. (Contested)

Hepatitis C

The NIH-funded SyNCH trial is the strongest negative: 154 patients with hepatitis C who had failed interferon got 420 or 700 mg three times daily — higher than usual doses — for 24 weeks. It made no difference to ALT, viral load or quality of life.⁵ Milk thistle doesn't treat viral hepatitis.

How to take it

• Form: a standardized extract labelled ~70–80% silymarin. Whole ground seed or tea gives very little, because silymarin is poorly water-soluble.
• Dose: trials range from 140 mg to 700 mg three times daily. The positive fibrosis trial used the high end (2.1 g/day).
• Absorption: oral bioavailability of silybin is poor (roughly 1% or less). Phytosome preparations, where silybin is complexed with phosphatidylcholine (sold as Siliphos), give several-fold higher blood levels, so a lower labelled dose can go further.
• With food: take with a meal that contains fat.
• Timescale: the fibrosis signal took 48 weeks. This is not an acute “liver detox” product — the idea of taking it the morning after drinking isn't what the trials tested.

Safety